Global biopharmaceutical company Mallinckrodt plc announced results of a retrospective, observational medical chart review subgroup analysis assessing real-world treatment outcomes among African Americans with advanced symptomatic sarcoidosis who initiated therapy with Acthar Gel (repository corticotropin injection).

Neurocrine Biosciences announced positive results from the company’s Phase III KINECT-HD study evaluating the efficacy of valbenazine in the treatment of chorea associated with Huntington’s Disease (HD).

SK Life Science Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd. – an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders – will present data from a pooled analysis from studies C013/C017 OLEs and C021 evaluating the cognitive and psychiatric treatment-related adverse events during adjunctive treatment with anti-seizure medication XCOPRI® (cenobamate tablets) CV at the American Academy of Neurology Annual Meeting, held in-person in Seattle April 2–7, 2022.

A new position paper from noted thought leaders and the Association of Clinical Research Professionals provides the much-needed voice of the clinical trial professional.

Led by new CEO Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals has a stated ambition to transition the RNA interference therapeutics trailblazer to a top 5 biotech – measured by market capitalization – within the next five years.

Emergent BioSolutions came into 2022 after a challenging year that saw the company lose a lucrative contract with the U.S. government following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine. 

Affini-T Therapeutics, a new cell therapy company launched by researchers from Fred Hutchinson Cancer Center, made its public debut at the 2022 J.P. Morgan Healthcare Conference with a mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.

Since acquiring Allergan for $63 billion in 2019, AbbVie said it’s “tracking well” against the financial commitment the company made when striking the deal. Chief Financial Officer Rob Michael said at the 2022 J.P. Morgan Healthcare Conference the company is exceeding AbbVie’s revenue expectations in the aesthetics market, led by Botox.

Amgen Chief Executive Officer Robert Bradway is excited about 2022. During his presentation at the J.P. Morgan Healthcare Conference, Bradway said things are lining up for long-term growth for the California-based company. 

The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start with deal announcements and plans to drive biopharma companies through the year.